Novo Nordisk seeks U.S., European approval of diabetes drug

05/27/2008 | Bloomberg

Danish firm Novo Nordisk A/S is seeking marketing approval for diabetes treatment liraglitude in the U.S. and Europe in a bid to launch the drug next year. Liraglitude is expected to compete with similar drugs being developed by Sanofi-Aventis and Novartis. The drug is based on glucagon-like peptide-1, a hormone that activates insulin production in the pancreas.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA